

## The CytoTools AG successfully placed a new tranche of the convertible bond for over 3 million euros

- Issue was oversubscribed, small shareholders were also active
- CytoTools obtained a gross issue revenue of 3 million euros
- Already committed medium and long-term oriented institutional investors played a very important role

Darmstadt, 3rd May 2019 – The CytoTools AG (WKN: A0KFRJ; ISIN: DE000A0KFRJ1) has successfully issued a further tranche of the convertible bond on the authorisation of the AGM, dated 10th August 2017. As well as the American investor Yorkville, a German institutional investor was over-proportionally active, resulting in an oversubscription. Furthermore, as previously, small shareholders participated in the capitalization measure.

The convertible bond with a total nominal value of EUR 3,000,000.00 is subdivided into 30 convertible bonds with a nominal value of EUR 100,000.00 each. The lifetime of the interest-free convertible bond begins on 30th April 2019 and the repayment of the non-converted bonds takes place on 30<sup>th</sup> January 2020. The bond sum was oversubscribed, so that a corresponding allocation was necessary. After conversations with the investors, the board of CytoTools expects a high degree of interest in a conversion.

Among other matters, investments in the existing German production line for the manufacture of DermaPro® are to be financed by the bond. The primary target here is obtaining the corresponding necessary acceptance by the authorities within the scope of the approval process in the coming year. This should ensure a rapid production start after completion of the phase III trials. The European market is to be supplied by the German production line, whereas the Indian market will be supplied by the production facilities in India by the license partner Centaur located there.

*This press release contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.*

### About CytoTools

CytoTools AG is a German biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (62%) and CytoPharma GmbH (50%).

## *Corporate News*



# CytoTools

**Contact:**

CytoTools AG  
Dr. Mark Andre Freyberg  
CEO  
Klappacher Str. 126  
D-64285 Darmstadt  
Tel.: +49-6151-95158-12  
Fax: +49-6151-95158-13  
E-Mail: [freyberg@cytotools.de](mailto:freyberg@cytotools.de)  
[www.cytotools.de](http://www.cytotools.de)

UBJ. GmbH  
Ingo Janssen  
Haus der Wirtschaft  
Kapstadtring 10  
D-22297 Hamburg  
Tel.: +49-40-6378-5410  
Fax.: +49-40-6378-5423  
E-Mail: [ir@ubj.de](mailto:ir@ubj.de)